Written Informed Consent Act
- Sponsor
- Sen. Sheehy, Tim [R-MT]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Dec 2, 2025
Bottom line
The bill mandates that the Department of Veterans Affairs obtain written informed consent from veterans before prescribing a broader range of powerful medications, including psychotropics and narcotics.
What it actually does
This bill directs the Secretary of Veterans Affairs to update an existing Veterans Health Administration (VHA) directive, VHA directive 1005, which currently mandates informed consent for long-term opioid therapy for pain. The update would expand this requirement to include written informed consent for five additional categories of medications: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics.
Proponents argue
Supporters argue that this bill enhances patient autonomy and ensures that veterans are fully informed about the potential risks, benefits, and alternatives of powerful medications, particularly those affecting mental health and pain management. They contend it protects vulnerable veterans from potential over-prescription or adverse effects by requiring a clear, documented understanding of their treatment plan.
Opponents contend
Critics might argue that while informed consent is crucial, expanding the written consent requirement to these broad categories of medications could create significant administrative burdens for VA healthcare providers, potentially delaying access to necessary treatment for veterans, especially in urgent situations. Some may also contend that existing verbal consent and patient education protocols are already sufficient.
The bill is exceptionally short and straightforward, making it very accessible for any reader to understand its core purpose quickly.
Section 2
Expansion of Informed Consent Directive
This provision mandates that the Secretary of Veterans Affairs revise an existing Veterans Health Administration (VHA) directive, specifically directive 1005, which currently governs informed consent for long-term opioid therapy. The revision requires that the informed consent process outlined in that directive be extended to cover five additional classes of medications: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. This means veterans would need to provide written informed consent before receiving these medications from the VA.
Supporters argue
Supporters argue that requiring written informed consent for these powerful medications ensures veterans are fully aware of potential side effects, risks, and benefits, empowering them to make truly informed decisions about their care. This measure is seen as a vital safeguard, particularly for medications with significant psychiatric or addictive potential, promoting patient safety and ethical medical practice.
Critics contend
Critics contend that while informed consent is important, mandating written consent for such a broad range of commonly prescribed medications could create unnecessary administrative hurdles. They argue this might delay access to critical treatments, especially for veterans in acute mental health crises or severe pain, and could overburden VA staff, diverting resources from direct patient care.
Tradeoffs
This provision navigates the tension between enhancing patient autonomy and safety through rigorous informed consent, and the potential for increased administrative burden and delays in accessing necessary medical care within a large healthcare system like the VA. It balances the ethical imperative of full disclosure against the practicalities of efficient healthcare delivery.